Management of Hyperglycemia in Post-Stroke Diabetic Patients

Introduction to Hyperglycemia Management

The American Heart Association/American Stroke Association recommends treating elevated glucose concentrations in the range of 140-180 mg/dL, and reserves aggressive intervention for persistent hyperglycemia >200 mg/dL during the first 24 hours after stroke 1
The American Diabetes Association recommends starting subcutaneous basal-bolus insulin regimen at 0.3 units/kg/day total daily dose, divided as half basal insulin once daily and half rapid-acting insulin before meals if oral intake is adequate 1

Intravenous insulin infusion is not indicated for mild hyperglycemia, and tight glucose control (80-110 mg/dL) using insulin infusions has demonstrated increased incidence of systemic and cerebral hypoglycemic events and possibly increased mortality risk in patients more than 2 weeks post-stroke 2
In elderly patients with multiple comorbidities, hypoglycemia may be more immediately dangerous than moderate hyperglycemia due to age-related reduced counter-regulatory hormone responses 1, 3

Warfarin has no role in managing hyperglycemia, and the patient is already appropriately managed with antiplatelet therapy for secondary stroke prevention 4
There is no indication for anticoagulation based on the information provided, such as atrial fibrillation or cardioembolic source 4

Initiate subcutaneous basal-bolus insulin regimen targeting glucose range of 140-180 mg/dL, with monitoring of glucose every 6 hours initially and checking potassium levels before and during insulin therapy to avoid hypokalemia, as recommended by the American Geriatrics Society 1
Avoid glucose levels <80 mg/dL as hypoglycemia is particularly dangerous in elderly patients with diabetes who are at increased risk of severe hypoglycemic events 1, 3

Never use sliding-scale insulin alone as the single regimen, as it results in undesirable hypoglycemia and hyperglycemia with increased risk of hospital complications, according to the American Diabetes Association 1
Avoid sulfonylureas, particularly glyburide and chlorpropamide, in elderly patients due to their prolonged half-life and escalating hypoglycemia risk with age, as explicitly contraindicated by the American Geriatrics Society 1, 3

For patients with multiple comorbidities, target HbA1c of 8% is appropriate rather than aggressive control, as recommended by the American Diabetes Association to avoid hypoglycemia risks that outweigh benefits 1, 5
Blood pressure target should be <140/90 mmHg given the diabetes and stroke history, with ACE inhibitors or ARBs as preferred agents 4, 5

Regular glucose monitoring is essential to titrate insulin doses and prevent both hyperglycemia and hypoglycemia, with self-monitoring of blood glucose helping to reduce serious hypoglycemia risk in older adults using insulin 3
Assess for hypoglycemia awareness at every visit, as impaired hypoglycemia awareness is common in elderly patients and increases risk 3

Elderly hospitalized patients often experience failure of regulatory mechanisms, especially reduced release of glucagon and epinephrine in response to hypoglycemia, and fail to perceive neuroglycopenic and autonomic hypoglycemic symptoms, which can delay response to correct hypoglycemic episodes, according to the American Diabetes Association guidelines 6